ASCO GU 2020

REVIEW UroToday

Viewing 1-20 of 222 articles

Randomized phase 2 study of sipuleucel-T (Sip-T) with or without radium-233 (Ra-223) in men with bone metastatic castration-resistant prostate cancer - Poster

ASCO GU 2020: Results from BLASST-1 - Nivolumab, Gemcitabine, and Cisplatin in Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy.

ASCO GU 2020: Combining Chemotherapy with Novel Agents, Opportunities, and Challenges.

ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective

ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Pathologists Perspective

ASCO GU 2020: Efficacy of Olaparib by Prior Taxane Use in Patients with Metastatic Castration-Resistant Prostate Cancer and Homologous Recombination Repair Gene Alterations: The PROfound Trial

ASCO GU 2020: Can Advanced Seminoma be Managed with a Risk Stratified Approach?

ASCO GU 2020: A Phase II Study of Talazoparib in Men with DNA Damage Repair Mutations and Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: (NEO-BLADE) Phase II Randomized Placebo-Controlled Neoadjuvant Trial of Nintedanib or Placebo with Gemcitabine and Cisplatin in Locally Advanced Muscle Invasive Bladder Cancer

ASCO GU 2020: Assessment of Inherited DNA Repair Defects in African-American and Caucasian Men with Prostate Cancer

ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial

ASCO GU 2020: Results from ATLAS, a Phase 2, Open-Label Trial: Rucaparib for Recurrent, Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2020: Phase Ib Study of Niraparib plus Androgen Receptor-Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: The Efficacy of Two Cycles of Neoadjuvant Chemotherapy for Upper Tract Urothelial Carcinoma Patients.

ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist

ASCO GU 2020: The Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma

ASCO GU 2020: A Phase I/II Study of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cancer that Progressed on Prior Anti-Angiogenic Therapy

ASCO GU 2020: Overall Survival Results for Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer — CALYPSO trial

ASCO GU 2020: Phase II Study of Cabazitaxel plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: Novel Drugs for Clear Cell Renal Cell Carcinoma

1
2
3
4
5
6
7
8
9
10